Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 4/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475130 | 0.98 | PNMT (0.62) | PNMTTAAR1IGF1RALOX15MAOB | |
| SCHEMBL6481869 | 0.96 | PNMT (0.64) | PNMTTAAR1IGF1RALOX15MAOB | |
| SCHEMBL2300678 | 0.92 | PNMT (0.69) | PNMTTAAR1IGF1RALOX15MAOB | |
| SCHEMBL4714764 | 0.82 | PNMT (0.73) | PNMTTAAR1IGF1RALOX15SIGMAR1 | |
| SCHEMBL31497388 | 0.82 | PNMT (0.73) | PNMTTAAR1IGF1RALOX15SIGMAR1 | |
| SCHEMBL11332031 | 0.80 | PNMT (0.70) | PNMTTAAR1IGF1RALOX15SIGMAR1 | |
| SCHEMBL12040578 | 0.80 | SIGMAR1 (0.64) | PNMTTAAR1IGF1RALOX15MAOB | |
| SCHEMBL11332990 | 0.80 | PNMT (0.70) | PNMTTAAR1IGF1RALOX15SIGMAR1 | |
| SCHEMBL11331998 | 0.80 | PNMT (0.70) | PNMTTAAR1IGF1RALOX15SIGMAR1 | |
| SCHEMBL11324805 | 0.80 | PNMT (0.70) | PNMTTAAR1IGF1RALOX15SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6972287-B1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | PFIZER INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | AUGELLI-SZAFRAN CORINNE ELIZAB (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1225886-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2000076489-A2 | METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-4786755-A | ANTAGONISTS, ENZYME INHIBITORS, MEDIATOR RELEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0206567-A2 | Compounds of formula [1,1'-biphenyl]-2-carboxylic acid, 2'-[[[(substituted)phenyl]-(substituted)amino]carbonyl]-, pharmaceutical compositions comprising the compounds, and a process for preparing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-12-30 | — | — | EP | disclosed |
| US-4602023-A | Diphenic acid monoamides | WARNER-LAMBERT COMPANY (US) | 1986-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220235-A1 | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits | APP, PSEN1, BACE1 | PNMT 1508/4885TAAR1 1933/4885IGF1R 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.